Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.54 USD | -4.09% | -6.59% | +121.20% |
Jun. 02 | Transcript : Cullinan Therapeutics, Inc. - Special Call | |
Jun. 01 | Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+121.20% | 1.3B | |
+48.64% | 56.65B | |
-6.44% | 39.44B | |
+37.38% | 39.03B | |
+14.28% | 26.75B | |
-11.17% | 26.86B | |
-21.40% | 19.03B | |
+25.64% | 12.26B | |
+0.96% | 12.28B | |
+27.04% | 12.04B |
- Stock Market
- Equities
- CGEM Stock
- News Cullinan Therapeutics, Inc.
- Cullinan Oncology : Morgan Stanley Adjusts Cullinan Oncology's Price Target to $43 From $40, Maintains Overweight Rating